Syngene International Bags ₹43 Crore Tax Refund After Court Wins

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorRiya Kapoor|Published at:
Syngene International Bags ₹43 Crore Tax Refund After Court Wins
Overview

Syngene International Limited has secured a tax refund of ₹43.15 crore, including interest, following tax litigation resolutions for Assessment Year (AY) 2016-17. This follows favourable High Court orders for earlier periods (AY 2010-13). The company anticipates a reduction in contingent liability for AY 2016-17 and expects no material financial impact from these resolutions.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

Syngene International Bags ₹43 Crore Tax Refund After Court Wins

Syngene International Limited has received a tax refund of ₹43,15,79,510, including interest, following resolutions in its tax litigation for Assessment Year (AY) 2016-17. The company also secured favorable High Court orders for AY 2010-11, AY 2011-12, and AY 2012-13, involving an adjustment amount of ₹48,90,84,008.

Key Tax Dispute Resolution Details

Syngene International Limited announced it has received an order dated February 6, 2026, giving effect to a favorable decision by the National Faceless Appeal Centre (NFAC) for AY 2016-17. This order, communicated on March 28, 2026, confirms a refund of ₹43,15,79,510, including interest, stemming from tax litigation.

This follows earlier positive developments, including a writ petition allowed by the Hon'ble High Court of Karnataka for AY 2010-11, AY 2011-12, and AY 2012-13, which involved an adjustment amount of ₹48,90,84,008. Out of this, ₹22,69,95,456 was adjusted towards AY 2016-17.

The original demand raised by the Assessing Officer for AY 2016-17, via an order dated December 27, 2018, was ₹72,33,63,020. Syngene's appeal against this demand has now seen partial allowance by the NFAC.

The company stated that it anticipates no material impact on its financials, operations, or overall business activities from these resolutions, but expects a decrease in contingent liability related to AY 2016-17.

Why This Resolution Matters

This tax litigation resolution brings greater certainty for Syngene regarding its past tax liabilities. The significant refund amount, while not expected to materially alter financials, will bolster cash flow. The reduction in contingent liability also cleans up the balance sheet, removing potential future obligations.

Background on Syngene's Tax Cases

Syngene has a history of navigating tax disputes. In a prior, significant High Court case for AY 2010-11, AY 2011-12, and AY 2012-13, the Karnataka High Court ruled in favor of Syngene, directing a refund of approximately ₹48.90 crore plus interest.

More recently, penalty proceedings initiated by the National Faceless Assessment Centre for AY 2018-19 were dropped following relief on disallowed expenses, providing closure on that specific tax matter. These resolutions collectively signify Syngene's successful engagement with tax authorities and appellate bodies.

Immediate Impacts

  • Cash Inflow: The company will receive a tax refund of over ₹43 crore, improving its liquidity.
  • Reduced Contingent Liability: The resolution for AY 2016-17 is expected to lower the company's contingent liabilities.
  • Financial Clarity: Closure on these specific tax matters reduces uncertainty around past financial reporting.
  • Operational Focus: Freeing up resources and management attention from ongoing tax disputes.

Potential Risks to Monitor

While the company anticipates no material financial impact, the original demand for AY 2016-17 was substantial, indicating the scale of disputes. Investors should monitor if other assessment years beyond those mentioned currently have unresolved tax litigations. The statement of "no material impact" suggests that while positive, these resolutions are not transformative to the company's overall financial standing.

Industry Context: India's CRO/CDMO Sector

Syngene operates within India's burgeoning contract research and manufacturing (CRO/CDMO) sector, competing with players like Jubilant Biosys, Anthem Biosciences, IQVIA, and Eurofins Advinus. This sector is characterized by significant R&D investment and growth potential, with the Indian CRO market projected to reach USD 130 billion by 2029. Syngene's ability to resolve tax disputes efficiently reflects a level of operational and financial maturity comparable to established players in this competitive landscape.

Financial Snapshot

  • Contingent liabilities related to AY 2016-17 are expected to decrease following these resolutions. (Period: As of filing date).
  • In FY24, Syngene saw its total liabilities increase by 6% to ₹61 billion, while current liabilities decreased by 3.7% to ₹11 billion. (FY24)

Next Steps for Investors

  • Refund Receipt: Confirmation of the actual receipt of the ₹43.15 crore tax refund.
  • Financial Reporting: Any updates in Syngene's financial statements reflecting the reduced contingent liabilities.
  • Ongoing Litigations: Continued monitoring for any new or ongoing tax disputes concerning other assessment years.
  • Management Commentary: Future updates from management on tax strategy and risk management.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.